News

23andMe’s Personal Genome Service Pharmacogenetic Reports test just got approved by the FDA. The first direct-to-customer screening option of its kind to secure FDA approval, the test is designed to detect potential genetic variants in charge of one’s ability to metabolize certain medications. Learn more about this big win for 23andMe in this article.

Embark has published its first scientific research, which conveys the company’s commitment to ending all preventable diseases in dogs. The project, which is the biggest initiative of its kind to date, was launched to answer why some dogs have blue eyes. Learn more about this exciting genome-wide association study in this article.

Ancestry recently updated its algorithm in an effort to provide more precise ethnicity estimates. While it seems that the majority of users are satisfied with the changes, some customers are disappointed in the DNA testing giant. Read our report to learn more about the backlash Ancestry is currently facing.

Ancestry, the leader in the field of genetic genealogy, has turned its 30-year experience into actionable data that will provide its existing and future users with much more precise ethnic estimates. Read all about this major algorithm update here and learn how to connect with your true genetic roots anywhere in the world.

MyHeritage’s free upload service just got an upgrade. As of September 12, 2018, users can upload tests based on the Global Screening Array chip, including 23andMe v5 and Living DNA tests. By uploading their DNA data now, users get to enjoy full access to multiple exciting MyHeritage features free of charge. Find out more in our detailed report.

23andMe is severely limiting access to its rich database by disabling its API (application programming interface). This move will have great repercussions on dozens of app developers currently using the data to work on their software. Read all about this decision and find out what the company’s representatives had to say about it.

23andMe has rolled out a new update designed to enrich its Ancestry Composition report regarding regions in Africa and East Asia. Read this post to learn all about this impressive new addition and what it means for users with ancestry roots in those regions.

Insurance companies have always been looking for ways to cut their costs and risks. Now, the increasingly popular at-home DNA tests are offering them the perfect way to avoid providing coverage to those who may need it the most. Discover how insurers can use your DNA test results to deny coverage or charge more and how to prevent this from happening.

23andMe’s recently signed deal with GlaxoSmithKline has prompted the DNA testing company to introduce new rules on the collection, retention, sharing, and use of consumers’ genetic data. Discover what these new privacy rules entail and how they affect the users’ right to decide how their genetic information is handled and shared with third parties.

23andMe and GSK signed a 4-year deal to combine their respective assets in order to identify novel drug targets, enable faster progression of clinical programs, and tackle new subsets of diseases. 23andMe welcomes all customers who’d like to participate in future research projects. Read more about this exciting collaboration in this article.